AA
KDNY

AlphaCentric Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

AlphaCentric Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,500
Closed -$40K – 225
2020
Q4 		$40K Buy
+2,500
New +$37.7K 0.02% 191

Other funds holding KDNY

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AlphaCentric Advisors's KDNY Position: Q1 2021 in Review

AlphaCentric Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2021, closing a stake of 2,500 shares — an estimated $40K sold.

AlphaCentric Advisors first reported a position in KDNY in Q4 2020 and held it in 1 quarter. The position peaked at $40K in Q4 2020. 77 funds tracked by Wall St. Rank hold KDNY as of Q1 2021.

  • AlphaCentric Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • AlphaCentric Advisors sold 2,500 Chinook Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $40K.
  • AlphaCentric Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • AlphaCentric Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $40K in Q4 2020.
  • 77 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2021.

Based on AlphaCentric Advisors's 13F filing for Q1 2021, filed 9 Mar 2022.